Ares-Serono Initiates Rebif v. Avonex Trial, May Beat Exclusivity Clock
Executive Summary
Ares-Serono has initiated a 600-patient trial to test the efficacy of Rebif against Biogen's Avonex.
You may also be interested in...
Serono Rebif Interferon Beta-1a Treatment U.S. Launch Expected Mid-2002
Serono expects to launch its interferon beta-1a treatment Rebif in the U.S. by mid-2002 after receiving the results from a head-to-head study comparing the multiple sclerosis biologic with Biogen's Avonex.
Serono Rebif Interferon Beta-1a Treatment U.S. Launch Expected Mid-2002
Serono expects to launch its interferon beta-1a treatment Rebif in the U.S. by mid-2002 after receiving the results from a head-to-head study comparing the multiple sclerosis biologic with Biogen's Avonex.
Serono Ovidrel
Filing for approval of the recombinant human chorionic gonadotropin is expected in both the U.S. and Europe by the end of the year, VP-Investor Relations & Scientific Affairs Andrew Galazka, MD, told the Warburg Dillon Read Conference Sept. 29. Phase III studies were completed in the second quarter (1"The Pink Sheet" Oct. 11, p. 22)